162
Views
14
CrossRef citations to date
0
Altmetric
CASE REPORT

Neuroleptic malignant syndrome induced by ziprasidone on the second day of treatment

, , MD, , &
Pages 42-44 | Received 08 Dec 2005, Published online: 12 Jul 2009

References

  • American Psychiatric Association. 2000. Diagnostic and Statistical Manual of Mental Disorders, 4th Text Revision. Washington, DC: American Psychiatric Association.
  • Anne WS, Lorraine AL, Howard HR, Jr, Stevin HZ. Ziprasidone: A novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol 2001; 425: 197–201
  • Bora E, Gönül AS, Akdeniz F, Vahip S. Neuroleptic malignant-like syndrome induced with low-dose quetiapine treated with electroconvulsive therapy. Eur Psychiatry 2003; 18: 322–323
  • Colloberative Working Group. Adverse effects of the atypical antipsychotics. J Clin Psychiatry 1998; 12: 17–22
  • Chouinard G, Ross-Chouinard A, Annable L, Jones BD. Extrapyramidal symptom rating scale. Can J Neurol Sci 1980; 7: 233
  • Elechi CA. Neuroleptic malignant syndrome complicating tetanus treated with chlorpromazine. Trop Doct 1992; 22: 92–93
  • Gray NS. Ziprasidone-related neuroleptic malignant syndrome in a patient with Parkinson's disease: A diagnostic challenge. Hum Psychopharmacol 2004; 19: 205–207
  • Hasan S, Buckley P. Novel antipsychotics and the neuroleptic malignant syndrome: A review and critique. Am J Psychiatry 1998; 155: 1113–1116
  • Leibold J, Patel V, Hasan RA. Neuroleptic malignant syndrome associated with ziprasidone in an adolescent. Clin Ther 2004; 26: 1105–1108
  • Lew TY, Tollefson G. Chlorpromazine-induced neuroleptic malignant syndrome and its response to diazepam. Biol Psychiatry 1983; 18: 1441–1446
  • Mahmood T, Warren JP. Neuroleptic malignant syndrome from chlorpromazine: case report. J R Coll Gen Pract 1989; 39: 211
  • Rasmussen KG. Risk Factors for neuroleptic malignant syndrome. Am J Psychiatry 1998; 155: 1639–1640
  • Sadock BJ, Sadock VA (eds). 2000. Kaplan and Sadock's Comprehensive Textbook of Psychiatry. 7th ed. New York, NY: Lippincott, Williams and Wilkins p 2266.
  • Sadock BJ, Sadock VA, editors. 2003. Kaplan and Sadock's synopsis of psychiatry: Behavioral sciences – clinical psychiatry. 9th ed. Philadelphia, PA: Lippincott, Williams and Wilkins. p 998.
  • Shad P. Pharmacodynamic and pharmacokinetic factors in a cese of neuroleptic malignant syndrome. J Clin Psychopharmacol 1998; 18: 346–347
  • Sing KJ, Ramaekers GM, Van Harten PN. Neuroleptic malignant syndrome and quetiapine. Am J Psychiatry 2002; 159: 149–150

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.